UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY

REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 1, 2006

OR

TRANSITION REPORT

PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition

period from________to_______

COMMISSION FILE

NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235

East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip

code)

(212) 573-2323

(Registrant's telephone number)

Indicate by check mark whether the registrant (1) has

filed all reports required to be filed by Section 13 or 15(d) of the

Securities Exchange Act of 1934 during the preceding 12 months (or for such

shorter period that the registrant was required to file such reports) and (2)

has been subject to such filing requirements for the past 90 days.

YES X NO

Indicate by check mark whether the registrant is a large

accelerated filer, an accelerated filer, or a non-accelerated filer. See

definition of "accelerated filer and large accelerated filer" in

Rule 12b-2 of the Exchange Act (Check one):

Large accelerated filer X

Accelerated Filer Non-accelerated

filer

Indicate by check mark whether the registrant is a shell

company (as defined in Rule 12b-2 of the Exchange Act).

YES NO X

At October 31, 2006, 7,210,444,662 shares of the

issuer's voting common stock were outstanding.

FORM 10-Q

For the Quarter

Ended

October 1, 2006

Table

of Contents

PART I. FINANCIAL

INFORMATION

Page

Item 1.

Financial Statements:

Condensed

Consolidated Statements of Income for the three months and nine months ended October

1, 2006 and October 2, 2005

Condensed

Consolidated Balance Sheets as of October 1, 2006 and

December 31, 2005

Condensed

Consolidated Statements of Cash Flows for the nine months ended October 1,

2006 and October 2, 2005

Notes to

Condensed Consolidated Financial Statements

Review Report

of Independent Registered Public Accounting Firm

25

Item 2.

Management's

Discussion and Analysis of Financial Condition and Results of Operations

26

Item 3.

Quantitative

and Qualitative Disclosures About Market Risk

57

Item 4.

Controls and

Procedures

57

PART II. OTHER

INFORMATION

Item 1.

Legal

Proceedings

58

Item 1A.

Risk Factors

59

Item 2.

Unregistered

Sales of Equity Securities and Use of Proceeds

59

Item 3.

Defaults Upon

Senior Securities

59

Item 4.

Submission of

Matters to a Vote of Security Holders

59

Item 5.

Other

Information

59

Item 6.

Exhibits

60

Signature

61

PART

I - FINANCIAL INFORMATION

Item 1. Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

Nine Months Ended

(millions,

except per common share data)

Oct. 1,

2006

Oct. 2,

2005

Oct. 1,

2006

Oct. 2,

2005

Revenues

12,280

11,263

35,768

34,858

Costs

and expenses:

Cost of sales(a)

1,962

1,611

5,423

5,250

Selling, informational and administrative expenses(a)

3,751

3,526

11,027

10,958

Research and development expenses(a)

1,902

1,739

5,187

5,287

Amortization of intangible assets

798

833

2,446

2,569

Merger-related in-process research and development

charges

1,390

513

1,652

Restructuring charges and merger-related costs

249

303

816

782

Other (income)/deductions - net

(343)

(151)

(958)

703

Income from continuing operations before provision

for taxes on income and minority interests

3,961

2,012

11,314

7,657

Provision for taxes on income

717

530

1,769

2,642

Minority interests

10

Income from continuing operations

3,239

1,479

9,535

5,009

Discontinued operations:

Income from discontinued operations - net

of tax

120

107

330

299

Gains on sales of discontinued

operations - net of tax

23

44

Discontinued operations - net of tax

123

110

353

343

Net income

3,362

1,589

9,888

5,352

Earnings

per common share - basic:

Income from continuing operations

0.45

0.20

1.31

0.68

Discontinued operations - net of tax

0.02

0.02

0.05

0.05

Net income

0.47

0.22

1.36

0.73

Earnings

per common share - diluted:

Income from continuing operations

0.44

0.20

1.30

0.67

Discontinued operations - net of tax

0.02

0.02

0.05

0.05

Net income

0.46

0.22

1.35

0.72

Weighted-average shares used to calculate earnings

per common share:

Basic

7,228

7,333

7,275

7,372

Diluted

7,251

7,382

7,306

7,424

Cash

dividends paid per common share

0.24

0.19

0.72

0.57

(a)

Exclusive

of amortization of intangible assets, except as disclosed in Note 12B, Goodwill

and Other Intangible Assets: Other Intangible Assets.

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(millions

of dollars)

Oct. 1,

2006*

Dec. 31,

2005**

ASSETS

Current Assets

Cash and cash

equivalents

1,177

2,247

Short-term

investments

11,654

19,979

Accounts

receivable, less allowance for doubtful accounts

9,177

9,103

Short-term

loans

460

510

Inventories

6,167

5,478

Prepaid

expenses and taxes

3,281

2,859

Assets of

discontinued operations and other assets held for sale

6,805

6,659

Total current assets

38,721

46,835

Long-term

investments and loans

2,845

2,497

Property, plant and equipment, less

accumulated depreciation

16,417

16,233

Goodwill

21,051

20,985

Identifiable

intangible assets, less accumulated amortization

25,323

26,244

Other assets,

deferred taxes and deferred charges

4,228

4,176

Total assets

108,585

116,970

LIABILITIES

AND SHAREHOLDERS' EQUITY

Current Liabilities

Short-term

borrowings, including current portion of long-term debt

2,508

11,589

Accounts

payable

1,742

2,073

Dividends

payable

1,772

Income taxes

payable

5,209

3,618

Accrued compensation

and related items

1,533

1,602

Other current

liabilities

5,271

6,521

Liabilities of

discontinued operations and other liabilities held for sale

1,423

1,237

Total current liabilities

17,688

28,412

Long-term debt

5,561

6,347

Pension benefit

obligations

2,636

2,681

Postretirement

benefit obligations

1,368

1,424

Deferred taxes

8,838

9,707

Other

noncurrent liabilities

2,782

2,635

Total liabilities

38,873

51,206

Shareholders' Equity

Preferred stock

146

169

Common stock

441

439

Additional

paid-in capital

68,865

67,759

Employee

benefit trust, at fair value

(845)

(923)

Treasury stock

(44,256)

(39,767)

Retained

earnings

43,991

37,608

Accumulated

other comprehensive income

1,370

479

Total shareholders' equity

69,712

65,764

Total liabilities and shareholders'

equity

108,585

116,970

* Unaudited.

** Condensed from audited

financial statements.

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Nine Months Ended

(millions

of dollars)

Oct. 1,

2006

Oct. 2,

2005

Operating Activities:

Net income

9,888

5,352

Adjustments to reconcile net income to net cash

provided by operating activities:

Depreciation and amortization

4,026

4,143

Share-based compensation expense

506

121

Merger-related in-process research and development

charges

513

1,652

Intangible asset impairments and other associated

non-cash charges

--

1,216

Gains on disposal of investments, products and

product lines

(201)

(58)

Gains on sales of discontinued operations

(37)

(72)

Deferred taxes from continuing operations

(1,333)

(1,088)

Other deferred taxes

67

(33)

Other non-cash adjustments

180

290

Changes in assets and liabilities (net of businesses

acquired and divested)

(491)

(1,527)

Net

cash provided by operating activities

13,118

9,996

Investing

Activities:

Purchases of property, plant and equipment

(1,438)

(1,493)

Purchases of short-term investments

(8,472)

(16,840)

Proceeds from redemptions of short-term investments

17,346

23,179

Purchases of long-term investments

(835)

(650)

Proceeds from redemptions of long-term investments

229

655

Purchases of other assets

(118)

(392)

Proceeds from sales of other assets

Proceeds from the sales of businesses, products and

product lines

22

108

Acquisitions, net of cash acquired

(1,989)

(2,104)

Other investing activities

(82)

238

Net

cash provided by investing activities

4,666

2,707

Financing

Activities:

Increase in short-term borrowings, net

993

Principal payments on short-term borrowings

(11,721)

(5,274)

Proceeds from issuances of long-term debt

1,051

Principal payments on long-term debt

(55)

(1,042)

Purchases of common stock

(4,496)

(3,415)

Cash dividends paid

(5,211)

(4,177)

Stock option transactions and other

593

346

Net cash used in financing activities

(18,846)

(13,548)

Effect of exchange-rate changes on cash and cash

equivalents

(8)

(4)

Net decrease in cash and cash equivalents

(1,070)

(849)

Cash and cash equivalents at beginning of period

2,247

1,808

Cash and cash equivalents at end of period

1,177

959

Supplemental Cash Flow Information:

Cash paid during the period for:

Income taxes

2,031

3,738

Interest

579

485

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER

INC AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of

Presentation

We prepared the condensed

consolidated financial statements following the requirements of the Securities

and Exchange Commission (SEC) for interim reporting. As permitted under those

rules, certain footnotes or other financial information that are normally

required by accounting principles generally accepted in the United States of

America (GAAP) can be condensed or omitted. Balance sheet amounts and operating

results for subsidiaries operating outside the U.S. are as of and for the

three-month and nine-month periods ended August 27, 2006 and August 28,

2005.

We made certain reclassifications to

the 2005 condensed consolidated financial statements to conform to the 2006

presentation. These reclassifications are primarily related to discontinued

operations (see Note 3, Discontinued Operations), as well as to better

reflect jurisdictional netting of deferred taxes.

Revenues, expenses, assets and

liabilities can vary during each quarter of the year. Therefore, the results

and trends in these interim financial statements may not be representative of

those for the full year.

We are responsible for the unaudited

financial statements included in this document. The financial statements

include all normal and recurring adjustments that are considered necessary for

the fair presentation of our financial position and operating results.

The information included in this

Quarterly Report on Form 10-Q should be read in conjunction with the

consolidated financial statements and accompanying notes included in Pfizer's

Annual Report on Form 10-K for the year ended December 31, 2005.

Note 2. Acquisitions

On May 16, 2006, we completed the

acquisition of all of the outstanding shares of Rinat Neuroscience Corp., a

biologics company with several new

central-nervous-system product candidates. In connection with the

acquisition, as part of our preliminary purchase price allocation, we recorded $478 million,

pre-tax, in Merger-related in-process research and development charges.

On February 28, 2006, we completed

the acquisition of the sanofi-aventis worldwide rights, including patent rights

and production technology, to manufacture and sell Exubera, an inhaled form of

insulin for use in adults with type 1 and type 2 diabetes, and the

insulin-production business and facilities located in Frankfurt, Germany,

previously jointly owned by Pfizer and sanofi-aventis, for approximately $1.4 billion

(including transaction costs). In connection with the acquisition, as part of

our final purchase price allocation, we recorded an intangible asset for

developed technology rights of approximately $1.0 billion, inventory valued

at $218 million and goodwill of approximately $166 million, all of

which have been allocated to our Pharmaceutical segment. The amortization of the

developed technology rights is primarily included in Cost of Sales. Prior

to the acquisition, in connection with our collaboration agreement with

sanofi-aventis, we recorded a research and development milestone due to us from

sanofi-aventis of approximately $118 million ($71 million, after tax)

in the first quarter of 2006 in Research and development expenses upon

the approval of Exubera in January 2006 by the Food and Drug Administration

(FDA).

On September 14, 2005, we completed

the acquisition of all of the outstanding shares of Vicuron Pharmaceuticals,

Inc. (Vicuron), a biopharmaceutical company focused on the development of novel

anti-infectives, for approximately $1.9 billion in cash (including

transaction costs). The allocation of the purchase price includes in-process

research and development of approximately $1.4 billion, which was expensed

and included in Merger-related in-process research and development charges,

and goodwill of $243 million, which has been allocated to our Pharmaceutical

segment. Neither of these items was deductible for tax purposes.

On April 12, 2005, we completed the

acquisition of Idun Pharmaceuticals, Inc. (Idun), a biopharmaceutical company

focused on the discovery and development of therapies to control apoptosis, and

on August 15, 2005, we completed the acquisition of all outstanding shares of

Bioren Inc. (Bioren), which focuses on technology for optimizing antibodies.

The aggregate cost of these and other smaller acquisitions was approximately

$340 million for the nine months ended October 2, 2005.

Note 3. Discontinued

Operations

We evaluate our businesses and

product lines periodically for strategic fit within our operations. As a result

of our evaluation, we decided to sell a number of businesses and product lines,

certain of which qualified for Discontinued operations treatment:

In June 2006,

we entered into an agreement to sell our Consumer Healthcare business for

approximately $16.6 billion in cash. This business comprises

substantially all of our former Consumer Healthcare segment and other associated

amounts, such as purchase-accounting impacts and merger-related costs, and

restructuring and implementation costs related to our Adapting to Scale (AtS)

productivity initiative, previously reported in the Corporate/Other segment. In

addition, certain manufacturing facility assets and liabilities, which were

previously part of our Pharmaceutical or Corporate/Other segment, are

included in the planned sale of the Consumer Healthcare business. In

connection with the decision to sell this business, for all periods

presented, the operating results associated with this business that will be

discontinued have been reclassified into Discontinued operations - net of

tax in the condensed consolidated statements of income, and the assets

and liabilities associated with this business that will be sold have been

reclassified into Assets/Liabilities of discontinued operations and other

assets/liabilities held for sale, as appropriate, on the condensed consolidated

balance sheets. The divestiture of the Consumer Healthcare business is

expected to close in late 2006 and is subject to customary closing

conditions, including receipt of regulatory approvals.

In the third

quarter of 2005, we sold the last of three European generic pharmaceutical

businesses, which we had included in our Pharmaceutical segment, for 4.7 million

euros (approximately $5.6 million) and recorded a loss of $3 million

($2 million, net of tax) in Gains on sales of discontinued operations

- net of tax in the condensed consolidated statement of income for the

three months and nine months ended October 2, 2005.

In the first

quarter of 2005, we sold the second of three European generic pharmaceutical

businesses, which had been included in our Pharmaceutical segment, for 70 million

euros (approximately $93 million) and recorded a gain of $57 million

($36 million, net of tax) in Gains on sales of discontinued

operations - net of tax in the condensed consolidated statement of

income. In addition, we recorded an impairment charge of $9 million ($6 million,

net of tax) related to the last of the three European generic pharmaceutical businesses

in Income from discontinued operations - net of tax in the condensed

consolidated statement of income for the nine months ended October 2, 2005.

The following amounts, primarily related

to our Consumer Healthcare business, have been segregated from continuing

operations and included in Discontinued operations - net of tax in the condensed

consolidated statements of income:

Three

Months Ended

Nine

Months Ended

(in millions)

Oct. 1,

2006

Oct. 2,

2005

Oct. 1,

2006

Oct. 2,

2005

Revenues

974

932

2,920

2,883

Pre-tax income

of discontinued businesses

178

174

493

465

Provision for

taxes on income

(58)

(67)

(163)

(166)

Income from discontinued

operations - net of tax

120

107

330

299

Pre-tax gains on sales of

discontinued businesses

37

72

Provision for taxes on gains

(3)

(4)

(14)

(28)

Gains on sales

of discontinued operations - net of tax

23

44

Discontinued operations-net of tax

123

110

353

343

The following assets and liabilities,

primarily related to our Consumer Healthcare business, have been segregated and

included in Assets of discontinued operations and other assets held for sale

and Liabilities of discontinued operations and other liabilities held for

sale, as appropriate, in the condensed consolidated balance sheets:

(in millions)

Oct. 1,

2006

Dec. 31,

2005

Accounts receivable, less allowance

for doubtful accounts

778

661

Inventories

518

561

Prepaid expenses and taxes

64

71

Property, plant and equipment, less

accumulated depreciation

1,023

1,002

Goodwill

2,751

2,789

Identifiable intangible assets,

less accumulated amortization

1,651

1,557

Other assets, deferred taxes and

deferred charges

20

18

Assets of discontinued operations and

other assets held for sale

6,805

6,659

Current liabilities

681

538

Other

742

699

Liabilities of

discontinued operations and other liabilities held for sale

1,423

1,237

Net cash flows of our discontinued

operations estimated from each of the categories of operating, investing and

financing activities were not significant for the nine months ended October 1,

2006 and October 2, 2005.

Note 4. Adoption of New

Accounting Standards

On January 1, 2006, we adopted the

provisions of Statement of Financial Accounting Standards (SFAS) No. 123R,

Share-Based Payment, as supplemented by the interpretation provided by SEC Staff

Accounting Bulletin No. 107, issued in March 2005. (SFAS 123R replaced SFAS

123, Stock-Based Compensation, issued in 1995.) We have elected the

modified prospective application transition method of adoption and, as such,